Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 340

1.

Association of Community Factors with Hospital-onset Clostridioides (Clostridium) difficile Infection: A Population Based U.S.-wide Study.

Zacharioudakis IM, Zervou FN, Shehadeh F, Mylona EK, Mylonakis E.

EClinicalMedicine. 2019 Feb 19;8:12-19. doi: 10.1016/j.eclinm.2019.02.001. eCollection 2019 Feb.

PMID:
31193719
2.

Correlation of antimicrobial prescription rate and county income in medicare part D.

Volpi C, Shehadeh F, Mylonakis E.

Medicine (Baltimore). 2019 May;98(22):e15914. doi: 10.1097/MD.0000000000015914.

3.

Cost-effectiveness of molecular diagnostic assays for the therapy of severe sepsis and septic shock in the emergency department.

Zacharioudakis IM, Zervou FN, Shehadeh F, Mylonakis E.

PLoS One. 2019 May 24;14(5):e0217508. doi: 10.1371/journal.pone.0217508. eCollection 2019.

4.

Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections: A Diagnostic Accuracy Study.

Nguyen MH, Clancy CJ, Pasculle AW, Pappas PG, Alangaden G, Pankey GA, Schmitt BH, Rasool A, Weinstein MP, Widen R, Hernandez DR, Wolk DM, Walsh TJ, Perfect JR, Wilson MN, Mylonakis E.

Ann Intern Med. 2019 May 14. doi: 10.7326/M18-2772. [Epub ahead of print]

PMID:
31083728
5.

The Effect of Influenza Vaccination on Mortality and Risk of Hospitalization in Patients With Heart Failure: A Systematic Review and Meta-analysis.

Poudel S, Shehadeh F, Zacharioudakis IM, Tansarli GS, Zervou FN, Kalligeros M, van Aalst R, Chit A, Mylonakis E.

Open Forum Infect Dis. 2019 Apr 2;6(4):ofz159. doi: 10.1093/ofid/ofz159. eCollection 2019 Apr.

6.

Cost-effectiveness of rapid diagnostic assays that perform directly on blood samples for the diagnosis of septic shock.

Shehadeh F, Zacharioudakis IM, Zervou FN, Mylonakis E.

Diagn Microbiol Infect Dis. 2019 Mar 3. pii: S0732-8893(18)30384-5. doi: 10.1016/j.diagmicrobio.2019.02.018. [Epub ahead of print]

PMID:
30922592
7.

Carriers of Clostridioides (Clostridium) difficile: To the Center of Focus for Controlling the Rate of Infection.

Zervou FN, Zacharioudakis IM, Mylonakis E.

Clin Infect Dis. 2019 Mar 14. pii: ciz210. doi: 10.1093/cid/ciz210. [Epub ahead of print] No abstract available.

PMID:
30901033
8.

Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings.

Liu H, Shukla S, Vera-González N, Tharmalingam N, Mylonakis E, Fuchs BB, Shukla A.

Front Cell Infect Microbiol. 2019 Feb 28;9:37. doi: 10.3389/fcimb.2019.00037. eCollection 2019.

9.

Rapid Isolation and Concentration of Pathogenic Fungi Using Inertial Focusing on a Chip-Based Platform.

Fuchs BB, Eatemadpour S, Martel-Foley JM, Stott S, Toner M, Mylonakis E.

Front Cell Infect Microbiol. 2019 Feb 12;9:27. doi: 10.3389/fcimb.2019.00027. eCollection 2019.

10.

A Systematic Review and Meta-analysis of Antibiotic Treatment Duration for Bacteremia Due to Enterobacteriaceae.

Tansarli GS, Andreatos N, Pliakos EE, Mylonakis E.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02495-18. doi: 10.1128/AAC.02495-18. Print 2019 May.

PMID:
30803971
11.

Current Status and Trends in Alternative Models to Study Fungal Pathogens.

Junqueira JC, Mylonakis E.

J Fungi (Basel). 2019 Jan 26;5(1). pii: E12. doi: 10.3390/jof5010012.

12.

In uncomplicated acute appendicitis, 61% of patients initially treated with antibiotics had not had appendectomy at 5 years.

Kalligeros M, Mylonakis E.

Ann Intern Med. 2019 Jan 15;170(2):JC10. doi: 10.7326/ACPJC-2019-170-2-010. No abstract available.

PMID:
30641561
13.

Cross-Domain and Viral Interactions in the Microbiome.

Rowan-Nash AD, Korry BJ, Mylonakis E, Belenky P.

Microbiol Mol Biol Rev. 2019 Jan 9;83(1). pii: e00044-18. doi: 10.1128/MMBR.00044-18. Print 2019 Mar. Review.

PMID:
30626617
14.

Anti-Candida albicans Activity of Thiazolylhydrazone Derivatives in Invertebrate and Murine Models.

Cruz LIB, Lopes LFF, de Camargo Ribeiro F, de Sá NP, Lino CI, Tharmalingam N, de Oliveira RB, Rosa CA, Mylonakis E, Fuchs BB, Johann S.

J Fungi (Basel). 2018 Dec 12;4(4). pii: E134. doi: 10.3390/jof4040134.

15.

The Cost-Effectiveness of Corticosteroids for the Treatment of Community-Acquired Pneumonia.

Pliakos EE, Andreatos N, Tansarli GS, Ziakas PD, Mylonakis E.

Chest. 2019 Apr;155(4):787-794. doi: 10.1016/j.chest.2018.11.001. Epub 2018 Nov 15.

PMID:
30448195
16.

Procalcitonin-guided antibiotic prescribing did not reduce antibiotic use in suspected LRTI in the ED.

Tansarli GS, Mylonakis E.

Ann Intern Med. 2018 Oct 16;169(8):JC39. doi: 10.7326/ACPJC-2018-169-8-039. No abstract available.

PMID:
30326083
17.

Vulnerability of long-term care facility residents to Clostridium difficile infection due to microbiome disruptions.

Fuchs BB, Tharmalingam N, Mylonakis E.

Future Microbiol. 2018 Oct;13:1537-1547. doi: 10.2217/fmb-2018-0157. Epub 2018 Oct 12. Review.

PMID:
30311778
18.

Reply to Burnham, Kakol, Vazquez-Guillamet.

Parente DM, Cunha CB, Mylonakis E, Timbrook TT.

Clin Infect Dis. 2018 Oct 10. doi: 10.1093/cid/ciy869. [Epub ahead of print] No abstract available.

PMID:
30304399
19.

Structure-activity relationships of pyrazole-4-carbodithioates as antibacterials against methicillin-resistant Staphylococcus aureus.

Majed H, Johnston T, Kelso C, Monachino E, Jergic S, Dixon NE, Mylonakis E, Kelso MJ.

Bioorg Med Chem Lett. 2018 Dec 1;28(22):3526-3528. doi: 10.1016/j.bmcl.2018.09.038. Epub 2018 Oct 3.

PMID:
30297281
20.

Galleria mellonella experimental model for bat fungal pathogen Pseudogymnoascus destructans and human fungal pathogen Pseudogymnoascus pannorum.

Fuchs BB, Chaturvedi S, Rossoni RD, de Barros PP, Torres-Velez F, Mylonakis E, Chaturvedi V.

Virulence. 2018;9(1):1539-1547. doi: 10.1080/21505594.2018.1518087.

21.

Discovery and Optimization of nTZDpa as an Antibiotic Effective Against Bacterial Persisters.

Kim W, Steele AD, Zhu W, Csatary EE, Fricke N, Dekarske MM, Jayamani E, Pan W, Kwon B, Sinitsa IF, Rosen JL, Conery AL, Fuchs BB, Vlahovska PM, Ausubel FM, Gao H, Wuest WM, Mylonakis E.

ACS Infect Dis. 2018 Nov 9;4(11):1540-1545. doi: 10.1021/acsinfecdis.8b00161. Epub 2018 Aug 28.

PMID:
30132650
22.

SDH2 is involved in proper hypha formation and virulence in Candida albicans.

Bi S, Lv QZ, Wang TT, Fuchs BB, Hu DD, Anastassopoulou CG, Desalermos A, Muhammed M, Wu CL, Jiang YY, Mylonakis E, Wang Y.

Future Microbiol. 2018 Aug;13:1141-1156. doi: 10.2217/fmb-2018-0033. Epub 2018 Aug 16.

PMID:
30113213
23.

Pathogenesis of the Candida parapsilosis Complex in the Model Host Caenorhabditis elegans.

Souza ACR, Fuchs BB, Alves VS, Jayamani E, Colombo AL, Mylonakis E.

Genes (Basel). 2018 Aug 8;9(8). pii: E401. doi: 10.3390/genes9080401.

24.

A phenylthiazole derivative demonstrates efficacy on treatment of the cryptococcosis & candidiasis in animal models.

Sá NP, Lima CM, A Dos Santos JR, Costa MC, de Barros PP, Junqueira JC, Vaz JA, Oliveira RB, Fuchs BB, Mylonakis E, Rosa CA, Santos DA, Johann S.

Future Sci OA. 2018 Apr 25;4(6):FSO305. doi: 10.4155/fsoa-2018-0001. eCollection 2018 Jul.

25.

Butenafine and analogues: An expeditious synthesis and cytotoxicity and antifungal activities.

Porras AMG, Terra BS, Braga TC, Magalhães TFF, Martins CVB, da Silva DL, Baltazar LM, Gouveia LF, de Freitas GJC, Santos DA, Resende-Stoianoff MA, Fuchs BB, Mylonakis E, de Freitas RP, de Fátima Â.

J Adv Res. 2018 Jun 21;14:81-91. doi: 10.1016/j.jare.2018.06.004. eCollection 2018 Nov.

26.

Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults.

Tansarli GS, Mylonakis E.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00635-18. doi: 10.1128/AAC.00635-18. Print 2018 Sep.

27.

The Cost-effectiveness of Antimicrobial Lock Solutions for the Prevention of Central Line-Associated Bloodstream Infections.

Pliakos EE, Andreatos N, Ziakas PD, Mylonakis E.

Clin Infect Dis. 2019 Jan 18;68(3):419-425. doi: 10.1093/cid/ciy511.

PMID:
29945237
28.

Galleria mellonella as a model invertebrate host for the study of muriform cells of dematiaceous fungi.

Huang X, Liu Y, Xi L, Zeng K, Mylonakis E.

Future Microbiol. 2018 Jul;13:1021-1028. doi: 10.2217/fmb-2018-0036. Epub 2018 Jun 21.

PMID:
29927339
29.

Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the "rubber effect".

Ziakas PD, Kourbeti IS, Poulou LS, Vlachogeorgos GS, Mylonakis E.

PLoS One. 2018 Jun 7;13(6):e0198674. doi: 10.1371/journal.pone.0198674. eCollection 2018.

30.

Antifungal activity directed toward the Cell wall by 2-cyclohexylidenhydrazo-4-phenyl-thiazole against Candida albicans.

de Sa NP, Possa AP, Perez P, Ferreira JMS, Fonseca NC, Lino CI, Cruz LB, de Oliveira RB, Rosa CA, Borelli BM, Mylonakis E, Fuchs BB, Johann S.

Infect Disord Drug Targets. 2018 May 30. doi: 10.2174/1871526518666180531101605. [Epub ahead of print]

PMID:
29852876
31.

The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.

Pliakos EE, Andreatos N, Shehadeh F, Ziakas PD, Mylonakis E.

Clin Microbiol Rev. 2018 May 30;31(3). pii: e00095-17. doi: 10.1128/CMR.00095-17. Print 2018 Jul. Review.

32.

Influence of subinhibitory concentrations of NH125 on biofilm formation & virulence factors of Staphylococcus aureus.

Liu Q, Zheng Z, Kim W, Burgwyn Fuchs B, Mylonakis E.

Future Med Chem. 2018 Jun 1;10(11):1319-1331. doi: 10.4155/fmc-2017-0286. Epub 2018 May 30.

33.

Use of T2MR in invasive candidiasis with and without candidemia.

Zacharioudakis IM, Zervou FN, Mylonakis E.

Future Microbiol. 2018 Aug;13:1165-1173. doi: 10.2217/fmb-2018-0079. Epub 2018 May 24. Review.

PMID:
29792512
34.

Propyl-5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC): a new bacteriostatic agent against methicillin-resistant Staphylococcus aureus.

Johnston T, Van Tyne D, Chen RF, Fawzi NL, Kwon B, Kelso MJ, Gilmore MS, Mylonakis E.

Sci Rep. 2018 May 4;8(1):7062. doi: 10.1038/s41598-018-25571-w.

35.

In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and -resistant isolates of Candida albicans.

de Sá NP, de Paula LFJ, Lopes LFF, Cruz LIB, Matos TTS, Lino CI, de Oliveira RB, de Souza-Fagundes EM, Fuchs BB, Mylonakis E, Johann S.

J Glob Antimicrob Resist. 2018 Sep;14:287-293. doi: 10.1016/j.jgar.2018.04.012. Epub 2018 Apr 30.

PMID:
29715565
36.

The impact of antibiotic prescription rates on the incidence of MRSA bloodstream infections: A county-level, US-wide analysis.

Andreatos N, Shehadeh F, Pliakos EE, Mylonakis E.

Int J Antimicrob Agents. 2018 Aug;52(2):195-200. doi: 10.1016/j.ijantimicag.2018.04.003. Epub 2018 Apr 12.

PMID:
29656062
37.

T2 Magnetic Resonance Assay: Overview of Available Data and Clinical Implications.

Zacharioudakis IM, Zervou FN, Mylonakis E.

J Fungi (Basel). 2018 Apr 4;4(2). pii: E45. doi: 10.3390/jof4020045. Review.

38.

Fecal Microbiome Among Nursing Home Residents with Advanced Dementia and Clostridium difficile.

Araos R, Andreatos N, Ugalde J, Mitchell S, Mylonakis E, D'Agata EMC.

Dig Dis Sci. 2018 Jun;63(6):1525-1531. doi: 10.1007/s10620-018-5030-7. Epub 2018 Mar 28.

39.

A new class of synthetic retinoid antibiotics effective against bacterial persisters.

Kim W, Zhu W, Hendricks GL, Van Tyne D, Steele AD, Keohane CE, Fricke N, Conery AL, Shen S, Pan W, Lee K, Rajamuthiah R, Fuchs BB, Vlahovska PM, Wuest WM, Gilmore MS, Gao H, Ausubel FM, Mylonakis E.

Nature. 2018 Apr 5;556(7699):103-107. doi: 10.1038/nature26157. Epub 2018 Mar 28.

40.

Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes.

Lin S, Chen R, Zhu S, Wang H, Wang L, Zou J, Yan J, Zhang X, Farmakiotis D, Tan X, Mylonakis E.

Mycopathologia. 2018 Aug;183(4):679-689. doi: 10.1007/s11046-018-0258-5. Epub 2018 Mar 23.

PMID:
29572768
41.

Strategies against methicillin-resistant Staphylococcus aureus persisters.

Kim W, Hendricks GL, Tori K, Fuchs BB, Mylonakis E.

Future Med Chem. 2018 Apr 1;10(7):779-794. doi: 10.4155/fmc-2017-0199. Epub 2018 Mar 23. Review.

42.

Fecal transplant by oral capsule was noninferior to delivery by colonoscopy for C difficile recurrence.

Tansarli GS, Mylonakis E.

Ann Intern Med. 2018 Mar 20;168(6):JC31. doi: 10.7326/ACPJC-2018-168-6-031. No abstract available.

PMID:
29554669
43.

Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori.

Tharmalingam N, Port J, Castillo D, Mylonakis E.

Sci Rep. 2018 Feb 27;8(1):3701. doi: 10.1038/s41598-018-22037-x.

44.

Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput Screen.

Tharmalingam N, Rajmuthiah R, Kim W, Fuchs BB, Jeyamani E, Kelso MJ, Mylonakis E.

Microb Drug Resist. 2018 Jun;24(5):666-674. doi: 10.1089/mdr.2017.0250. Epub 2018 Feb 20.

45.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).

Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J.

Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S10-S20. doi: 10.1016/j.cmi.2017.12.025. Epub 2018 Feb 6. Review.

46.

Lactobacillus paracasei 28.4 reduces in vitro hyphae formation of Candida albicans and prevents the filamentation in an experimental model of Caenorhabditis elegans.

de Barros PP, Scorzoni L, Ribeiro FC, Fugisaki LRO, Fuchs BB, Mylonakis E, Jorge AOC, Junqueira JC, Rossoni RD.

Microb Pathog. 2018 Apr;117:80-87. doi: 10.1016/j.micpath.2018.02.019. Epub 2018 Feb 9.

PMID:
29432910
47.

Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis.

Rossoni RD, de Barros PP, de Alvarenga JA, Ribeiro FC, Velloso MDS, Fuchs BB, Mylonakis E, Jorge AOC, Junqueira JC.

Biofouling. 2018 Feb;34(2):212-225. doi: 10.1080/08927014.2018.1425402. Epub 2018 Jan 30.

PMID:
29380647
48.

Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial.

Mylonakis E, Zacharioudakis IM, Clancy CJ, Nguyen MH, Pappas PG.

J Clin Microbiol. 2018 Mar 26;56(4). pii: e01756-17. doi: 10.1128/JCM.01756-17. Print 2018 Apr.

49.
50.

Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of Staphylococcus aureus.

Zheng Z, Liu Q, Kim W, Tharmalingam N, Fuchs BB, Mylonakis E.

Future Med Chem. 2018 Feb;10(3):283-296. doi: 10.4155/fmc-2017-0159. Epub 2018 Jan 15.

Supplemental Content

Loading ...
Support Center